Reassessment of reimbursement status of antidiabetic medicines (ATC group A10)
On 22 December 2009, the Danish Medicines Agency announced that we would begin our reassessment of the reimbursement status of a number of groups of medicines, including antidiabetics (ATC group A10). See link to the announcement in the box to the right.
Within a few months, the Reimbursement Committee will begin to discuss the reimbursement status of antidiabetic drugs. If the Reimbursement Committee recommends a change of the reimbursement status of these medicines, the Committee's recommendation will be submitted for consultation to companies, relevant scientific societies and relevant patient organisations.
Any comments that could be relevant to the Reimbursement Committee's discussions must reach us no later than 15 February 2012.
All comments that we receive during the process or as part of a consultation will be published on our website. The relevant scientific societies and patient organisations have been informed, see the list in the right-hand box.
In the box to the right, you can find a link to information on reassessment of reimbursement - including guidelines, a status overview of the individual groups of medicines, news in this area and the background for reassessing reimbursement as well as the material and minutes from the Reimbursement Committee meetings.